Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Strengthening Food Security and Nutrition for an Inclusive India
- 2 Protecting Children in the Digital Age: The Need for Safer Social Media
- 3 India's Bioeconomy Blueprint: NITI Aayog's Roadmap to 2035
- 4 Vision Document on Drug Control
- 5 India's Rural Credit System: Expanding Financial Inclusion and Agricultural Growth
- 6 AI in India's Judicial System: Balancing Innovation with Constitutional Values
- 7 India’s Seaward Foreign Policy: Securing Maritime Interests in a Changing World
- 8 Fast Track Courts: Strengthening the Integrity of Public Examinations
- 9 Strategic Roadmap for Making Ayurveda Global
- 10 The Growing Threat of Antimicrobial Resistance in India
